US3242190A - 3-hydroxy-5-aminomethylisoxazole compounds - Google Patents
3-hydroxy-5-aminomethylisoxazole compounds Download PDFInfo
- Publication number
- US3242190A US3242190A US41579564A US3242190A US 3242190 A US3242190 A US 3242190A US 41579564 A US41579564 A US 41579564A US 3242190 A US3242190 A US 3242190A
- Authority
- US
- United States
- Prior art keywords
- acid
- isoxazole
- solution
- hydroxy
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical class NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 title claims description 12
- 239000002253 acid Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 235000013350 formula milk Nutrition 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003610 charcoal Substances 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- -1 azidomethyl compound Chemical class 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 150000002545 isoxazoles Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- LCFSQWLCIUITOH-UHFFFAOYSA-N (3-bromo-1,2-oxazol-5-yl)methanamine Chemical compound NCC1=CC(Br)=NO1 LCFSQWLCIUITOH-UHFFFAOYSA-N 0.000 description 3
- MBTTWUDVHGZSIF-UHFFFAOYSA-N (3-phenylmethoxy-1,2-oxazol-5-yl)methanamine Chemical compound O1C(CN)=CC(OCC=2C=CC=CC=2)=N1 MBTTWUDVHGZSIF-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RHFWLPWDOYJEAL-UHFFFAOYSA-N 1,2-oxazol-3-amine Chemical compound NC=1C=CON=1 RHFWLPWDOYJEAL-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- HJSJUDGUMXEMAX-UHFFFAOYSA-N n-[(3-oxo-1,2-oxazol-5-yl)methyl]acetamide Chemical compound CC(=O)NCC1=CC(=O)NO1 HJSJUDGUMXEMAX-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- KYCWVOUDYZJUBJ-UHFFFAOYSA-N (3-chloro-1,2-oxazol-5-yl)methanol Chemical compound ClC1=NOC(=C1)CO.ClC1=NOC(=C1)CO KYCWVOUDYZJUBJ-UHFFFAOYSA-N 0.000 description 1
- IVMFFAPHOPXMAD-UHFFFAOYSA-N (3-methoxy-1,2-oxazol-5-yl)methanamine Chemical compound COC=1C=C(CN)ON=1 IVMFFAPHOPXMAD-UHFFFAOYSA-N 0.000 description 1
- DIIVXOUBNHJXED-UHFFFAOYSA-N (3-methoxy-1,2-oxazol-5-yl)methanol Chemical compound COC=1C=C(CO)ON=1 DIIVXOUBNHJXED-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NFCHMZFEFOKVDT-UHFFFAOYSA-N 3-bromo-5-(bromomethyl)-1,2-oxazole Chemical compound BrCC1=CC(Br)=NO1 NFCHMZFEFOKVDT-UHFFFAOYSA-N 0.000 description 1
- PNKXWZNWVHRIPS-UHFFFAOYSA-N 4-(aminomethyl)-1,2-oxazol-3-one Chemical compound NCC1=CONC1=O PNKXWZNWVHRIPS-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- ABSRTUPJGPVCBM-UHFFFAOYSA-N 5-(azidomethyl)-1,2-oxazol-3-one Chemical compound OC1=NOC(=C1)CN=[N+]=[N-] ABSRTUPJGPVCBM-UHFFFAOYSA-N 0.000 description 1
- DZYGNTRDQYBNTF-UHFFFAOYSA-N 5-(chloromethyl)-1,2-oxazol-3-one Chemical compound ClCC1=CC(=O)NO1 DZYGNTRDQYBNTF-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- LEVJVKGPFAQPOI-UHFFFAOYSA-N phenylmethanone Chemical compound O=[C]C1=CC=CC=C1 LEVJVKGPFAQPOI-UHFFFAOYSA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
Definitions
- a compound of general Formula II can be hydrogenated, for example, in the presence of palladium on charcoal or of Raney nickel as catalysts, in an organic solvent such as dioxan, ethanol, methanol or tetrahydrofuran, at room temperature.
- an organic solvent such as dioxan, ethanol, methanol or tetrahydrofuran, at room temperature.
- the compound of Formula I precipitates as hybrid ion and is thus, on the whole, no longer exposed to the action of hydrogen.
- Impurities and side products are soluble in organic solvents so that it is possible to forego the purification of the azidomethyl compound used for the hydrogenation.
- Azidomethyl compounds of the general Formula II are obtained, for example, by reacting, at room temperature or slightly raised temperature, a reactive ester of 3-alkoxyl-5-hydroxymethyl-isoxazole with sodium azide in a suitable organic solvent such as acetone.
- the compound of Formula I is also obtained by hydrogenolysing a compound of Formula III H CCO R wherein R represents the benzyl group, and if desired, converting the 3-hydroxy-5-aminomethyl-isoxazole into a salt with an inorganic or organic acid.
- the hydrogenolysis can be performed simultaneously, i.e. in the same step, as a hydrogenation according to the process described above.
- Another process for the production of the new isoxazole derivative of Formula I consists in reacting a reactive ester of 3-hydroxy-S-hydroxymethyl-isoxazole of Formula V with ammonia.
- Suitable reactive esters of compounds of Formula V are, in particular, the halides, such as chloride, bromide or iodide, and also sulphuric acid esters, e.g. esters of tolyl sulphonic acid or p-bromobenzene sulphonic acid or methylsulphonic acid.
- the compound of Formula V is dissolved in a low alkanol or in water, saturated with dry ammonia in the col-d and then kept for several hours at .a raised temperature in a closed vessel.
- a 3-hydroxy-S-halogenomethyl-isoxazole of Formula V is obtained, for example, from -halogen-[a43-dimethoxy-butyrohydroxamic acid, by treatment with hydrochloric acid.
- the new isoxazole derivative of Formula I is obtained by hydrolysing a compound of the general Formula VI wherein Ac is a low molecular acyl radical.
- the hydrolysis is preferably performed by treating the compound of general Formula VI with hydrochloric acid at boiling temperature.
- low molecular acyl radicals are the acetyl or benzoyl radical.
- the new isoxazole derivative or Formula I is converted into a salt with inorganic and organic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane disulphonic acid, fl-hydroxyethane, sulphonic acid, acetic acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid.
- inorganic and organic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane disulphonic acid, fl-hydroxyethane, sulphonic acid, acetic acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, malic acid, tartaric acid, citric
- Example 1 50 g. of the mixture of 3-chloro-5-hydroxymethyl isoxazole (3-chloro-5-isoxazole methanol) and 3-chloro- S-[tetrahydropyran-(Z)-oxymethyl]-isoxazole, and 80 g. (about 400% of the calculated amount) of potassium hydroxide are dissolved in 500 ml. of methanol and the solution is heated for 24 hours in an autoclave at 100-110. The dark methanol solution is decanted from the precipitated salt and concentrated in vacuo. The residue and the salt are both dissolved in 400 ml. of water, the solution is made acid with concentrated hydrochloric acid and extracted with ether in a 500 ml.
- the aqueous phase a dark alkaline solution
- the ether solution is dried over magnesium sulphate and concentrated, the residue is dissolved in 50 ml. of abs. ether and liberated from a few undissolved flakes by treatment with active charcoal.
- the 3-hydroxy-5-azidomethyl-isoxazole remains in the form of pale yellow crystal which melt at 7880.
- Example 2 (a) 600 ml. of ethanol and 600 ml. of tech. concentrated aqueous ammonia solution are mixed and the whole is saturated with ammonia at room temperature. 120.5 g. (0.5 mol) of 3-bromo-5-bromomethyl-isoxazole are added dropwise to this mixture at room temperature and the solution, which gradually becomes darker in colour, is left to stand for 24 hours. The reaction solution is then evaporated in vacuo to about 0.5 litre, and made acid with 2N hydrochloric acid. The resinous side products are removed by filtration with Hyflo and charcoal. The filtrate is washed twice with chloroform or methylene chloride and then made alkaline with concentrated sodium hydroxide solution to liberate the basic reaction product.
- the substance is dissolved in about 20 times the amount of water, methanol is added to the solution which is then filtered once or twice with charcoal through Hyflo. Tetrahydrofuran is added to the colourless filtrate at room temperature until crystallisation begins. After standing at room temperature, the substance is filtered off and, after drying for several days at 12 Torr. over phosphorus pentoxide in a desiccator it is sufficiently pure for analysis. It melts at 175 with decomposition.
- Example 3 (a) 8.80 g. (50 millimol) of 3-brom0-5-aminomethylisoxazole, 516 g. (100 millimol) of potassium hydroxide and 110 ml. of benzyl alcohol are heated for 10 hours at 180". On cooling to 20, five times the amount of ether are added to the reaction mixture which is then extracted twice with 200 ml. of 2N hydrochloric acid each time. The acid aqueous extract is washed four times with 300 ml. of ether each time, made alkaline and then extracted three times with methylene chloride.
- Example 4 (a) 2.7 ml. of abs. methanol are saturated at with dry hydrochloric acid gas, and then a mixture of 10.0 g. of 'y-chloroacetoacetic acid ester, 20.0 g. of orthoformic acid methyl ester and 13 g. of abs. methanol is added. The mixture is refluxed for 4 hours while excluding water. While still hot, the reaction mixture is poured into 200 ml. of ice water while stirring, the pH is immediately adjusted to 8 with 30% sodium hydroxide solution and it is extracted four times with ether. The ether extract is dried over magnesium sulphate. After evaporating off the ether, on fractional distillation of the remaining oil through a 5 cin. Vigreux column, a main fraction is obtained which boils at between 101 and 103 under 11 Torr. and which does not react with aqueous FeC1 solution.
- the FeCl positive eluate is collected an devaporated in vacuo at 40.
- the pale yellow crystalline residue is evaporated five times in vacuo with water until it contains no more acetic acid whereupon it is dried for -15 hours at 40 under 0.5 Torr.
- the pale yellow product obtained dissolves completely in abs. methanol and melts at 107-110.
- the eluates are tested by paper electrophoresis.
- the fraction containing the aminoxazolol has an alkaline reaction (pH 8) also after complete removal of the ammonia.
- the aminoisoxazol can be washed with water. After evaporating the fraction containing the aminoisoxazole, yellowish crystals remain: Recrystallisation from Water/ methanol yields 3-hydroxy-5-aminomethyl-isoxazole M.P. (with decomposition).
- Example 5 (a) 6.80 g. (33 millimol) of 3-benzyloxy-5-aminomethyl-isoxazole in 19 ml. (200 millimol) of acetic acid anhydride and 100 ml. of glacial acetic acid are heated for 15 hours in a steam bath. 100 ml. of methanol are added whereupon the whole is refluxed for 1 hour and then evaporated. The residue is taken up in 100 ml. of chloroform, washed with 2N sodium bicarbonate solution, water, 2N hydrochloric acid and again with water and dried over magnesium sulphate. After evaporation, crystals are obtained which, after recrystallisation from ether/penthane melt at 7376.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
United States Patent Ofiice 3,242,190 Patented Mar. 22, 1966 3,242,190 3-HYDROXY-5-AMINOMETHYLISUXAZOLE COMPOUNDS Franz Hailiger and Andre Gagneux, Basel, and Conrad Eugster, Zurich, Switzerland, assignors to Geigy Chemical Corporation, Greenburgh, N.Y., a corporation of Delaware No Drawing. Filed Dec. 3, 1964, Ser. No. 415,795 Claims priority, application Switzerland, Dec. 6, I963, 14,954/ 63 2 Claims. (Cl. 26d-3il7) This invention relates to a new isoxazole derivative as Well as processes for the production of this new compound which has valuable pharmacological properties. It has been found that the hitherto unknown 3-hydroxy- 5-amino-methyl-isoxazole (5-aminomethyl-3-isoxazolol of Formula I wherein R represents hydrogen or the benzyl group.
A compound of general Formula II can be hydrogenated, for example, in the presence of palladium on charcoal or of Raney nickel as catalysts, in an organic solvent such as dioxan, ethanol, methanol or tetrahydrofuran, at room temperature. In the hydrogenation, the compound of Formula I precipitates as hybrid ion and is thus, on the whole, no longer exposed to the action of hydrogen. Impurities and side products are soluble in organic solvents so that it is possible to forego the purification of the azidomethyl compound used for the hydrogenation.
Azidomethyl compounds of the general Formula II are obtained, for example, by reacting, at room temperature or slightly raised temperature, a reactive ester of 3-alkoxyl-5-hydroxymethyl-isoxazole with sodium azide in a suitable organic solvent such as acetone.
The compound of Formula I is also obtained by hydrogenolysing a compound of Formula III H CCO R wherein R represents the benzyl group, and if desired, converting the 3-hydroxy-5-aminomethyl-isoxazole into a salt with an inorganic or organic acid. The hydrogenolysis can be performed simultaneously, i.e. in the same step, as a hydrogenation according to the process described above.
(III) In addition, 3 hydroxy-S-aminomethyl isoxazole of Formula I is obtained by treating a compound of the Formula IV H(L- O O it wherein R" represents a low alkyl radical or the benzyl group, with hydrobromic acid, hydrochloric acid or with the hydrochloride or hydrobromide of optionally alkylsubstituted pyridine, the reaction being performed while heating, e.g. at temperatures between. about and C.
Starting compounds of Formulae III and IV wherein R and R" rpresent the benzyl group are obtained in the known way by, for example, heating 3-bromo-5-aminomethyl-isoxazole with benzyl alcohol for a few hours in the presence of alkali hydroxide. The compounds of Formula IV wherein R" is a low alkyl radical are obtained in the known manner by heating a low alkanol with 3-bromo-5-aminomethyl-isoxazole in the presence of alkali hydroxide.
Another process for the production of the new isoxazole derivative of Formula I consists in reacting a reactive ester of 3-hydroxy-S-hydroxymethyl-isoxazole of Formula V with ammonia.
The reaction is preferably performed in a closed vessel. Suitable reactive esters of compounds of Formula V are, in particular, the halides, such as chloride, bromide or iodide, and also sulphuric acid esters, e.g. esters of tolyl sulphonic acid or p-bromobenzene sulphonic acid or methylsulphonic acid.
The compound of Formula V is dissolved in a low alkanol or in water, saturated with dry ammonia in the col-d and then kept for several hours at .a raised temperature in a closed vessel.
A 3-hydroxy-S-halogenomethyl-isoxazole of Formula V is obtained, for example, from -halogen-[a43-dimethoxy-butyrohydroxamic acid, by treatment with hydrochloric acid.
Finally, the new isoxazole derivative of Formula I is obtained by hydrolysing a compound of the general Formula VI wherein Ac is a low molecular acyl radical. The hydrolysis is preferably performed by treating the compound of general Formula VI with hydrochloric acid at boiling temperature. Examples of low molecular acyl radicals are the acetyl or benzoyl radical.
Compounds of general For-mula VI are obtained, e.g. by hydrogenation of 3-benzyloxy-5-acylaminomethylisoxazoles with catalytically activated hydrogen at room temperature.
If desired, the new isoxazole derivative or Formula I is converted into a salt with inorganic and organic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane disulphonic acid, fl-hydroxyethane, sulphonic acid, acetic acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid.
In the above formulas, for instance in Formula I, and in the formulas given in the appended claims the nonionized structure of the compounds has been given for the sake of simplicity. In fact, the compound of Formula I exists always in its Zwitter ionic form, which is of the formula The following examples illustrate the performance of the processes according to the invention but are by no means the only methods of performing same. The temperatures are given in degrees centigrade.
Example 1 (a) 50 g. of the mixture of 3-chloro-5-hydroxymethyl isoxazole (3-chloro-5-isoxazole methanol) and 3-chloro- S-[tetrahydropyran-(Z)-oxymethyl]-isoxazole, and 80 g. (about 400% of the calculated amount) of potassium hydroxide are dissolved in 500 ml. of methanol and the solution is heated for 24 hours in an autoclave at 100-110. The dark methanol solution is decanted from the precipitated salt and concentrated in vacuo. The residue and the salt are both dissolved in 400 ml. of water, the solution is made acid with concentrated hydrochloric acid and extracted with ether in a 500 ml. Kutscher-Steudel apparatus for 5 hours. The ether solution is dried over mag; nesium sulphate and concentrated. The residue distills at 60-90 under 0.01 Torr. Halogen test negative. NMR spectrum agrees with 3-methoxy-5-hydroxymethyl-isoxazole but shows that in addition to the 5-hydroxymethyl compound, 25% of 5-tetrahydropyranyloxymethyl com- (pound is present.
(b) 30 g. of the mixture obtained according to (a) in 300 ml. of abs. benzene are stirred for 16 hours at 3040 with 15 ml. of phosphorus tribromide. The reaction mixture is washed twice with 300 ml. of ice water and once with 300 ml. of saturated sodium chloride solution, dried over sodium sulphate and concentrated. The S-methoxy- 5-bromomethyl-isoxazole passes over at 102104 on distilling under 12 Torr. Structural evidence by NMR spectrum.
19.2 g. (0.1 mol) of the above bromide dissolved in 150 ml. or acetone are added to a solution of 39 g. (0.6 mol) of sodium azide in 150 ml. of water and the whole is stirred for 12 hours at 30. After diluting with 250 ml. of Water, the mixture is extracted three times with 200 ml. of ether each time. The ether extracts are washed twice with 500 ml. of water each time, dried over magnesium sulphate and evaporated in vacuo at 30. 3- methoxy-S-azidomethyl-isoxazole, which decomposes explosively at 200, remains as a pale yellow liquid. The yield is quantitative. Structural evidence by NMR+IR spectrum.
((1) g. (32 millimol) of the product of (c) and g. (87 millimol) of pyridine hydrochloride are heated for 22 hours at 120 under an atmosphere of nitrogen. After cooling, 10 ml. of concentrated sodium hydroxide solution are added to the reaction mixture which has been dissolved in 100 ml. of water whereupon the alkaline solution is extracted twice with 200 ml. of ether each time. The organic phase is removed, washed with 300 ml. of water and 300 ml. of dilute hydrochloric acid, dried over magnesium sulphate and concentrated whereupon of the starting material is regained. The aqueous phase, a dark alkaline solution, is made acid to congo paper with concentrated hydrochloric acid and extracted with ether for 6 hours in a Kutscher-Steudel apparatus. The ether solution is dried over magnesium sulphate and concentrated, the residue is dissolved in 50 ml. of abs. ether and liberated from a few undissolved flakes by treatment with active charcoal. After distilling ofi the ether at 30 under reduced pressure, the 3-hydroxy-5-azidomethyl-isoxazole remains in the form of pale yellow crystal which melt at 7880.
(e) 6.7 g. (48 millimol) of the product of (d) are dissolved in ml. of abs. dioxan, 6 g. of 5% palladium charcoal are added and the whole is treated with hydrogen for 3 hours at 25 under normal pressure. The catalyst is filtered off, and the filtrate is washed with a little dioxan and slurried several times with water. The solution so obtained is evaporated, the residue is dissolved in a little water and clarified with active charcoal. The residue obtained on evaporating the clear solution is stirred for 1 hour in 50 ml. of methanol whereupon the greasy side products dissolve and the S-hydroxy-S-aminomethyl-isoxazole remains in crystalline form. It decomposes at On careful recrystallization from water and tetrahydrofuran, white crystals are obtained which decompose at (f) 5 ml. of ZN-hydrochloric acid in isopropanol are added to 1.5 of 3-hydroxy-5-aminomethyl-isoxazole under cooling with ice. Upon dropwise addition of methyl ethyl ketone, 3-hydroxy-5-ammoniummethyl-isoxazole chloride precipitates after several hours at 0. The precipitate is separated by filtration and dried.
Example 2 (a) 600 ml. of ethanol and 600 ml. of tech. concentrated aqueous ammonia solution are mixed and the whole is saturated with ammonia at room temperature. 120.5 g. (0.5 mol) of 3-bromo-5-bromomethyl-isoxazole are added dropwise to this mixture at room temperature and the solution, which gradually becomes darker in colour, is left to stand for 24 hours. The reaction solution is then evaporated in vacuo to about 0.5 litre, and made acid with 2N hydrochloric acid. The resinous side products are removed by filtration with Hyflo and charcoal. The filtrate is washed twice with chloroform or methylene chloride and then made alkaline with concentrated sodium hydroxide solution to liberate the basic reaction product. It is then extracted five times with chloroform or methylene chloride. The combined extracts are dried over potassium carbonate and evaporated in vacuo. The liquid which remains is dissolved in ether and any greasiness or cloudiness is removed by filtration with charcoal. After evaporating off the ether, 3-bromo-5-aminomethyl-isoxazole remains as a pale brown liquid and can be reacted without any further purification.
(b) 140 g. of potassium hydroxide (2.5 mol) are dissolved in 885 ml. of methanol, 88.5 g. (0.5 mol) of crude 3-bromo-S-aminomethyl-isoxazole are added and the whole is refluxed for 2030 hours. After cooling, potassium bromide and resinous parts are filtered 01f through Hyfio, the clear methanolic filtrate is evaporated and the residue is taken up in about 0.5 liters of water and extracted several times with chloroform. The combined extracts are dried over potassium carbonate and concentrated. Distillation of the residue at about 70 under 0.01 Torr. yields about 50-60% of the theoretically calculated amount of reaction product. However, according to NMR spectra, the colourless liquid also contains 20% of starting material in addition to the desired 3-methoxy-5-aminomethyl-isoxazole.
(c) 65 g. of the reaction product of (b) and 650 ml. of 24% hydrochloric acid are refluxed for 4 hours. The reaction solution is then diluted with the same volume of water and filtered with charcoal through Hyflo. The pale yellow solution is evaporated in vacuo, the residue is dried, dissolved in 650 ml. of methanol and 65 ml. of triethylamine are added. The clearly alkaline mixture is evaporated in vacuo, the residue is slurried in 650 ml. of fresh methanol, 325 ml. of tetrahydrofuran are added and the whole is cooled in a refrigerator. The 3-hydroxy- S-aminomethyl-isoxazole (5 aminomethyl-3-isoxazolol) which precipitates is washed first with methanol and then with ether.
To completely purify, the substance is dissolved in about 20 times the amount of water, methanol is added to the solution which is then filtered once or twice with charcoal through Hyflo. Tetrahydrofuran is added to the colourless filtrate at room temperature until crystallisation begins. After standing at room temperature, the substance is filtered off and, after drying for several days at 12 Torr. over phosphorus pentoxide in a desiccator it is sufficiently pure for analysis. It melts at 175 with decomposition.
Example 3 (a) 8.80 g. (50 millimol) of 3-brom0-5-aminomethylisoxazole, 516 g. (100 millimol) of potassium hydroxide and 110 ml. of benzyl alcohol are heated for 10 hours at 180". On cooling to 20, five times the amount of ether are added to the reaction mixture which is then extracted twice with 200 ml. of 2N hydrochloric acid each time. The acid aqueous extract is washed four times with 300 ml. of ether each time, made alkaline and then extracted three times with methylene chloride. After drying the combined methylene chloride extracts over magnesium sulphate and distilling off the solvent, a pale oil is obtained which can be identified by NMR spectrum clearly as a mixture of 95% of 3-benZyloxy-5-aminomethyl-isoxazole and 5% of benzyl alcohol.
(b) 1.02 g. (5 millimol) of 3-benZyloxy-5-aminomethyl-isoxazole in 50 ml. of abs. dioxan are hydrogenated in the presence of palladium charcoal catalyst (5%) under normal pressure and room temperature until 80% of the calculated, equimolar amount of hydrogen has been taken up. The reaction mixture is then filtered, the residue is washed with abs. dioxan and then diluted with 20 ml. of water whereupon the reaction product dissolves. After filtering off the catalyst, the aqueous solution is evaporated. The residue consists of pure 3-l1ydroxy-5- aminomethyl-isoxazole (S-aminomethyl 3 isoxazolol); M.P. 175 with decomposition.
Example 4 (a) 2.7 ml. of abs. methanol are saturated at with dry hydrochloric acid gas, and then a mixture of 10.0 g. of 'y-chloroacetoacetic acid ester, 20.0 g. of orthoformic acid methyl ester and 13 g. of abs. methanol is added. The mixture is refluxed for 4 hours while excluding water. While still hot, the reaction mixture is poured into 200 ml. of ice water while stirring, the pH is immediately adjusted to 8 with 30% sodium hydroxide solution and it is extracted four times with ether. The ether extract is dried over magnesium sulphate. After evaporating off the ether, on fractional distillation of the remaining oil through a 5 cin. Vigreux column, a main fraction is obtained which boils at between 101 and 103 under 11 Torr. and which does not react with aqueous FeC1 solution.
(b) A solution of 35.0 g. of hydroxylamine hydrochloride (0.5 mol) in 210 ml. of hot abs. methanol is cooled for a short time in an ice bath and, under an atmosphere of nitrogen, a solution of 42 g. of potassium hydroxide (0.75 mol) in 155 ml. of abs. methanol is so added that the temperature of the reaction solution does not rise above 20. After all the alkali has been added, the whole is stirred in the ice bath for 5 minutes. Then the mixture is filtered under suction through a glass frit and the residue is washed with a little methanol. A solution of 35.9 g. of -chloro-fi,,B-dimethoxybutyric acid ethyl ester in 20 ml. of methanol is added to the filtrate immediately and the mixture is left to stand for 96 hours at room temperature under an atmosphere of nitrogen. A few crystals are formed after some hours (KCl). The reaction solution is evaporated in vacuo, the residue is dissolved in twice the amount of water and the solution is separated on an anion exchange column (Dowex). The column is washed neutral with water and then eluted with 2N acetic acid. Just before the acid eluate, there is a small alkaline fraction which, towards the end, becomes positive to the FeCl test (wine red). The FeCl positive eluate is collected an devaporated in vacuo at 40. The pale yellow crystalline residue is evaporated five times in vacuo with water until it contains no more acetic acid whereupon it is dried for -15 hours at 40 under 0.5 Torr. The pale yellow product obtained dissolves completely in abs. methanol and melts at 107-110.
For analysis, it is recrystallised three times from acetone, then su blimed in a bulb tube at under 10* Torr. The white sublimate melts at 129131 with sintering above 124 (c) 5.0 g. of crude -chloro-fi,ti-dimethoxy-butyrohydroxamic acid in 130 ml. of glacial acetic acid are saturated with dry HCl white stirring with a magnetic stirrer first at room temperature and then at 0, whereupon it is left to stand for 16 hours at room temperature. The pale brown solution is evaporated at 40 in vacuo and the residue is evaporated three times with water. The yellow crystalline product so obtained is extracted twice with 130 ml. of warm ether each time, the yellow ether solution is filtered and evaporated whereupon pale yellow needles remain which melt at 90-95 The product which is still not quite pure is unstable. It can be purified by careful recrystallisation from carbon tetrachloride or acetone or by sublimation under high vacuum (in small portions). The pure product is consideraby more stable: white needles which melt at 97- 101 with sintering above about 80; strong acid reaction in aqueous solution.
(d) 3.1 g. of crude 3-hydroxy-5-chloromethyl-isoxazole in 40 ml. of abs. methanol are saturated with dry ammonia at 0 in an autoclave fitted with an inner glass container. The autoclave is then closed and maintained for 10 hours at 100. The dark brown reaction solution is evaporated in vacuo, the residue is taken up in water and filtered. The filtrate is separated by means of an ion exchange column (Dowex). It is eluted with water until a colourless neutral filtrate containing no chloride is obtained. The amnioisoxazolol desired all remains on the column and is eluted with 2% amomnia solution. (The eluates are tested by paper electrophoresis.) The fraction containing the aminoxazolol has an alkaline reaction (pH 8) also after complete removal of the ammonia. The aminoisoxazol can be washed with water. After evaporating the fraction containing the aminoisoxazole, yellowish crystals remain: Recrystallisation from Water/ methanol yields 3-hydroxy-5-aminomethyl-isoxazole M.P. (with decomposition).
Example 5 (a) 6.80 g. (33 millimol) of 3-benzyloxy-5-aminomethyl-isoxazole in 19 ml. (200 millimol) of acetic acid anhydride and 100 ml. of glacial acetic acid are heated for 15 hours in a steam bath. 100 ml. of methanol are added whereupon the whole is refluxed for 1 hour and then evaporated. The residue is taken up in 100 ml. of chloroform, washed with 2N sodium bicarbonate solution, water, 2N hydrochloric acid and again with water and dried over magnesium sulphate. After evaporation, crystals are obtained which, after recrystallisation from ether/penthane melt at 7376.
(b) 492 mg. (2 millimol) of 3*b6llZYl0XY-5-EICC'LY1- aminomethyl-isoxazole in 10 ml. of 95 ethanol or glacial acetic acid are hydrogenated under normal pressure at 20 over prehydrogenated 10% Pd/ charcoal. In 6 minutes 2 millimol of hydrogen are taken up. After filtering off the catalyst, on evaporating, 3-hydroxy-5-acetylaminomethyl-isoxazole is obtained, M.P. 132-135".
(c) 312 mg. (2 millimol) of 3-hydroxy-5-acetaminomethyl-isoxazole in 20 ml. of 2N hydrochloric acid are refluxed for 2% hours. After evaporation and drying for 2 hours over solid potassium hydroxide solution at 50 under 0.1 Torr., 3-hydroXy-5-arninomethyl-isoxazole hydrochloride is obtained, M.P. 160 (with decomposition).
What is claimed is:
1. A member selected from the group consisting of 3- hydroxy-S-aminomethyl-isoxazole and a pharmaceutically acceptable salt thereof With an acid.
2. 3-hydr0xy-S-ammoniummethyl-isoxazole chloride.
No references cited.
IRVING MARCUS, Primary Examiner.
Claims (1)
1. A MEMBER SELECTED FROM THE GROUP CONSISTING OF 3HYDROXY-5-AMINOMETHYL-ISOXAZOLE AND A PHARMOCEUTICALLY ACCEPTABLE SALT THEREOF WITH AN ACID.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1495463A CH427803A (en) | 1963-12-06 | 1963-12-06 | Process for the production of a new isoxazole derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3242190A true US3242190A (en) | 1966-03-22 |
Family
ID=4405150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US41579564 Expired - Lifetime US3242190A (en) | 1963-12-06 | 1964-12-03 | 3-hydroxy-5-aminomethylisoxazole compounds |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US3242190A (en) |
| AT (2) | AT249054B (en) |
| BE (1) | BE656759A (en) |
| CH (1) | CH427803A (en) |
| DE (1) | DE1445848A1 (en) |
| DK (4) | DK106796C (en) |
| ES (5) | ES306818A1 (en) |
| FR (2) | FR1427775A (en) |
| GB (1) | GB1034939A (en) |
| IL (1) | IL22568A (en) |
| NL (1) | NL6414138A (en) |
| SE (3) | SE301652B (en) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3544584A (en) * | 1964-09-14 | 1970-12-01 | Sankyo Co | Certain 5-alkyl-3-hydroxyisoxazoles |
| US6544998B2 (en) | 2000-11-30 | 2003-04-08 | Pfizer Inc | Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| US6720348B2 (en) | 2000-11-30 | 2004-04-13 | Pfizer Inc | Combination of gaba agonists and aldose reductase Inhibitors |
| US20050004106A1 (en) * | 2003-05-16 | 2005-01-06 | Pfizer Inc | Combinations of GABA modulators and anticonvulsants, and atypical antipsychotics |
| US20050182049A1 (en) * | 2004-01-29 | 2005-08-18 | Pfizer Inc | Combination of gamma-aminobutyric acid modulators and 5-HT1B receptor antagonists |
| US20070112017A1 (en) * | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20070244143A1 (en) * | 2006-03-08 | 2007-10-18 | Braincells, Inc | Modulation of neurogenesis by nootropic agents |
| US20080064671A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20080103165A1 (en) * | 2006-09-19 | 2008-05-01 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
| US20090325949A1 (en) * | 2006-05-09 | 2009-12-31 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2258359A2 (en) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| EP2275095A2 (en) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2343073A2 (en) | 2003-12-11 | 2011-07-13 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| EP2377530A2 (en) | 2005-10-21 | 2011-10-19 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK150615C (en) * | 1982-10-26 | 1987-11-09 | Cheminova As | METHOD FOR PREPARING SUBSTITUTED 3-ISOXAZOLOLS |
-
1963
- 1963-12-06 CH CH1495463A patent/CH427803A/en unknown
-
1964
- 1964-12-03 US US41579564 patent/US3242190A/en not_active Expired - Lifetime
- 1964-12-04 GB GB4931864A patent/GB1034939A/en not_active Expired
- 1964-12-04 NL NL6414138A patent/NL6414138A/xx unknown
- 1964-12-04 DE DE19641445848 patent/DE1445848A1/en active Pending
- 1964-12-04 AT AT1030064A patent/AT249054B/en active
- 1964-12-04 SE SE1469364A patent/SE301652B/xx unknown
- 1964-12-04 AT AT476065A patent/AT250348B/en active
- 1964-12-04 IL IL22568A patent/IL22568A/en unknown
- 1964-12-05 ES ES0306818A patent/ES306818A1/en not_active Expired
- 1964-12-05 DK DK599664A patent/DK106796C/en active
- 1964-12-05 ES ES0306817A patent/ES306817A1/en not_active Expired
- 1964-12-05 FR FR997579A patent/FR1427775A/en not_active Expired
- 1964-12-05 ES ES0306820A patent/ES306820A1/en not_active Expired
- 1964-12-05 ES ES0306819A patent/ES306819A1/en not_active Expired
- 1964-12-05 DK DK443965A patent/DK108169C/en active
- 1964-12-05 DK DK444065A patent/DK106797C/en active
- 1964-12-05 ES ES0306816A patent/ES306816A1/en not_active Expired
- 1964-12-05 DK DK444165A patent/DK106733C/en active
- 1964-12-07 BE BE656759D patent/BE656759A/xx unknown
-
1965
- 1965-03-04 FR FR7870A patent/FR4139M/fr not_active Expired
-
1967
- 1967-01-09 SE SE27767A patent/SE304513B/xx unknown
- 1967-01-09 SE SE27667A patent/SE303507B/xx unknown
Non-Patent Citations (1)
| Title |
|---|
| None * |
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3544584A (en) * | 1964-09-14 | 1970-12-01 | Sankyo Co | Certain 5-alkyl-3-hydroxyisoxazoles |
| US6544998B2 (en) | 2000-11-30 | 2003-04-08 | Pfizer Inc | Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| US6720348B2 (en) | 2000-11-30 | 2004-04-13 | Pfizer Inc | Combination of gaba agonists and aldose reductase Inhibitors |
| US20050004106A1 (en) * | 2003-05-16 | 2005-01-06 | Pfizer Inc | Combinations of GABA modulators and anticonvulsants, and atypical antipsychotics |
| EP2343073A2 (en) | 2003-12-11 | 2011-07-13 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| US20050182049A1 (en) * | 2004-01-29 | 2005-08-18 | Pfizer Inc | Combination of gamma-aminobutyric acid modulators and 5-HT1B receptor antagonists |
| EP2258359A2 (en) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| EP2275096A2 (en) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| EP2275095A2 (en) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A2 (en) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP2258357A2 (en) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP2377530A2 (en) | 2005-10-21 | 2011-10-19 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| US20070112017A1 (en) * | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20070244143A1 (en) * | 2006-03-08 | 2007-10-18 | Braincells, Inc | Modulation of neurogenesis by nootropic agents |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| US20090325949A1 (en) * | 2006-05-09 | 2009-12-31 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| EP2382975A2 (en) | 2006-05-09 | 2011-11-02 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20080064671A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20080103165A1 (en) * | 2006-09-19 | 2008-05-01 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2011063115A1 (en) | 2009-11-19 | 2011-05-26 | Braincells Inc. | Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis |
Also Published As
| Publication number | Publication date |
|---|---|
| ES306817A1 (en) | 1965-05-16 |
| ES306818A1 (en) | 1965-05-16 |
| AT250348B (en) | 1966-11-10 |
| FR4139M (en) | 1966-05-02 |
| BE656759A (en) | 1965-06-08 |
| CH427803A (en) | 1967-01-15 |
| DK106796C (en) | 1967-03-20 |
| SE303507B (en) | 1968-09-02 |
| AT249054B (en) | 1966-09-26 |
| GB1034939A (en) | 1966-07-06 |
| ES306816A1 (en) | 1965-05-16 |
| DK106797C (en) | 1967-03-20 |
| DE1445848A1 (en) | 1968-11-21 |
| ES306820A1 (en) | 1965-05-16 |
| IL22568A (en) | 1968-04-25 |
| SE301652B (en) | 1968-06-17 |
| ES306819A1 (en) | 1965-05-16 |
| DK106733C (en) | 1967-03-13 |
| FR1427775A (en) | 1966-02-11 |
| DK108169C (en) | 1967-10-02 |
| NL6414138A (en) | 1965-06-07 |
| SE304513B (en) | 1968-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3242190A (en) | 3-hydroxy-5-aminomethylisoxazole compounds | |
| US2883384A (en) | Production of reserpine and analogs thereof | |
| US3397209A (en) | 3-hydroxy-5-isoxazole-carboxamide | |
| US3644380A (en) | Preparation of 3-cyanopyridine | |
| SE430888B (en) | OPTICALLY ACTIVE LEFT ROTATING N- (1-ETHYL-2-PYRROLIDINYL-METHYL) -2-METOXY-5-SULFAMOYL BENZAMIDE AND PROCEDURE TO PREPARE THIS | |
| Saito et al. | On the alkaloids of white hellebore. III. Experiments on the constitution of jervine | |
| US2710299A (en) | Process for the production of crystalline vanillyl amides | |
| SU1556538A3 (en) | Method of producing pyrimidine derivatives | |
| JPS5953261B2 (en) | Method for producing 2(1H)-pyridone derivative | |
| US3144466A (en) | Diacyl esters of de-oleandrosehydroxyoleandomycin and process therefor | |
| US3304313A (en) | 2-(nu-phthalimidoacetyl-nu-cycloalkylmethyl)-aminobenzophenone derivatives | |
| Pelletier et al. | The pyrodelphonine chromophore. Crystal structures of pyrodelphinine and delphinine | |
| US2740781A (en) | 3, 26-dihydroxy-16, 22-imino-5-cholestenes, 3, 26-dihydroxy-16, 22-imino-5, 16, 20(22)-cholestatrienes and derivatives thereof | |
| JPS5910674B2 (en) | Manufacturing method of apovincamic acid ester | |
| US2695902A (en) | 2-methyl-3-(beta-chloroethyl)-4, 6-dichloro pyridine and method of making same | |
| US3103513A (en) | Process for preparing hexadehy- | |
| US2916495A (en) | Beta-thianaphthenylalkyl hydrazines and intermediates | |
| US3014925A (en) | Unsaturated mevalonic acid | |
| Robison et al. | Rauwolfia Alkaloids. XXXVI. 1 Non-hypotensive Sedatives Derived from Methyl Reserpate | |
| US3578670A (en) | Nicotinamide intermediates and process for preparing same | |
| SU725562A3 (en) | Method of preparing maleic acid salts of 2-phenyl-6-(1-oxy-2-tert-butylaminoethyl)-4h-pyrido(3,2-d)-1,3-dioxine | |
| US2655507A (en) | Pyrazole compounds | |
| US2140480A (en) | 3-keto-d-pentonic acid lactone and process for the manufacture of same | |
| US2165445A (en) | Preparation of phenyl methyl pyrazyl phenyl methyl pyrazolone | |
| Schaefgen et al. | Synthesis of an Octabasic Carboxylic Acid |